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Abstract
InpatientswithCrohn'sdiseaseandulcerativecolitisparenteralnutrition
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Zusammenfassung
Eine parenterale Ernährung (PE) ist indiziert bei Patienten mit Morbus
CrohnoderColitisulcerosa,wenneineenteraleErnährungnichtmöglich
ist bzw. aus medizinischen Gründen vermieden werden sollte. Bei
Morbus Crohn Patienten kann eine PE bei Manifestation im oberen
Dünndarm und Ileus- und Subileussymptomatik, Narben oder Darmfis-
teln indiziert sein. Die PE bedarf keiner speziellen Zusammensetzung
fürchronischentzündlicheDarmerkrankungen.InbeidenErkrankungen
sollte sich die PE aus 55–60% Kohlenhydraten, 25–30% Fett und
10–15%Aminosäurenzusammensetzen.DiePEunterstütztdieKorrek-
turderMangelernährung,vorallemdieAufnahmevonEnergie,Mineral-
stoffen, Spurenelementen, Mangel an Kalzium, Vitamin D, Folsäure,
Vitamin B 12, Zink. Im Falle einer notwendigen künstlichen Ernährung
beieinerschwerenakutenPankreatitisisteineenteraleErnährungeiner
parenteralen Ernährungsform eindeutig überlegen. Eine Unverträglich-
keit der enteralen Ernährung führt bei Komplikationen, wie Pseudozys-
ten,intestinaleundpankreatischeFisteln,pankreatischeAbszesseoder
pankreatischem Aszites zum Einsatz der TPE. Sollte eine enterale Er-
nährung nicht möglich sein, ist eine PE erst nach frühestens 5 Tagen
nach Klinikeintreffen zu empfehlen. Die TPE sollte bei milder akuter
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Glukose von max. 3–6 g/kg KG/Tag und Aminosäuren von 1,2–1,5
g/kg KG/Tag sollten zugeführt werden sowie eine zusätzliche Anreiche-
rung durch Glutamin von TPE sollte bei schweren Verlaufsformen einer
Pankreatitis erwogen werden.
Schlüsselwörter: chronisch entzündliche Darmerkrankungen, Morbus
Crohn, Colitis ulcerosa, Pankreatitis
Crohn's disease
Indication and time of parenteral
nutrition (PN)
• PN is indicated when enteral nutrition is not possible
or should be avoided for medical reasons (A).
• PN is indicated when there are signs/symptoms of
ileus or subileus in the small intestine, scars or intes-
tinal fistulae (C).
Substrate intake
• PN requires no specific compounding for chronic in-
flammatory bowel diseases.
• It should be composed of 55–60% carbohydrates,
25–30% lipids and 10–15% amino acids (A). No con-
clusive data is available on the use of admixtures in
the form of polyunsaturated fatty acids (C).
• PN helps in the correction of malnutrition, particularly
the intake of energy, minerals, trace elements, defi-




should be used due to the high incidence of malnutrition
in chronic inflammatory bowel disease. PN should be
administered via central venous access for osmolarity
over 800 mosmol/l and continuously over 24 hours.
Thedailyparenteralenergyintakeinwell-nourishedadult
patients should amount to 25–30 kcal/kg body weight.
During the first 24–48 hours, the PN administration
shouldbeslowlystartedwithaphaseofan“up-titration”,
starting with about 50% of the energy amount. The
volume should be adjusted to 30–40 ml/kg body weight,
depending on the loss of fluid. Concentrations of 4–6 g
glucose/kgbodyweight,1.5–2glipidsperkgbodyweight
and 1.5–2 g amino acids per kg body weight are recom-
mended [1].
PN is indicated in cases of toxic megacolon, malabsorp-
tion syndrome, particularly short bowel syndrome, insuf-
ficient growth and disturbance of growth in children as
wellaswhenenteralnutritionisnottolerated[2],[3],[4],
[5], [6], [7], [8], [9], [10].
PN presents no advantage if the disease is chronically
active (A). An increased rate of remission is not achieved
with PN, according to the official recommendations of
the American Gastroenterological Association (AGA). PN
has no influence on the surgical intervention rate. Ac-
cording to these recommendations, it is not necessary to
bypasstheintestinalpassagetoattainclinicalremission.
An optimal supply of nutrients improves bowel motility,
intestinal permeability and nutritional status, and lowers
inflammatoryreactions[8],[11].Malnutritionoftenoccurs
in patients with inflammatory bowel diseases. There are
extensive differences in the parameters for malnutrition
between Crohn’s disease and ulcerative colitis. Malnutri-
tion is diagnosed in 80% of Crohn's disease patients [5],
[9], [10], [11]. The severity of malnutrition depends on
the duration of the illness, activity of the inflammation,
the function of the small intestine and extent of the dis-
eased sections in the small intestine, and results in a
higher incidence of protein energy malnutrition as well
as specific substrate deficiency.
Clinical symptoms, inflammatory and nutritional param-
eters in Crohn's disease can improve under enteral/oral
nutrition [2], [6], [10], [12], [13], [14]. There is no stand-
ardised data available regarding the remission rate with







al nutrition. It is assumed that oral/enteral nutrition
provides faster stability in organ function of the small in-
testine.
Complications like venous thromboses, occlusion of the
central venous vessels, sepsis, cholestasis/cholangit-
is/cholecystitis, cholestatic liver dysfunction are associ-
ated with TPN [16], [17], [18], [19], [20], [21], [22], [23],
[24], [25], [26], [27]. Acute elevation in transaminases,
overall bilirubin and albumin are characteristics of PN
metabolic complications [16], [17], [18], [19], [20], [21],
[22], [24], [25].
Numerousstudiesshowthatcatheter-relatedsepsisoccur
on an average once or twice every two years in patients
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bowel syndrome, as a result of chronic inflammatory
boweldiseases.Recurringcatheterinfectionswithseptic
components occur during hospital stays in dependence
of central access catheter models and in dependence of
training and care standards in the hospital in patients
who are not receiving long-term PN [28]. There are no
advantages of PN therapy over enteral nutrition therapy
regarding fistula healing. No differences can be seen in
the rate of survival.
Ulcerative colitis
Indication and time of PN
• PN is indicated when enteral nutrition is not possible
or should be avoided for medical reasons (A).
Substrate intake
• PN requires no specific compounding for chronic in-
flammatory bowel diseases (A).
• It should be composed of 55–60% carbohydrates,
25–30% lipids and 10–15% amino acids (A). No con-
clusive data is available on the use of admixtures in
the form of polyunsaturated fatty acids (C).
• PN helps in the correction of malnutrition, particularly
the intake of energy, minerals, trace elements, defi-
ciency of calcium, vitamin D, folic acid, vitamin B12,
and zinc (A). In addition, the intake of vitamins, trace
elements and minerals can be orally or intravenously
substituted irrespective of PN.
Commentary
No significant improvement in clinical parameters was
observed in patients with ulcerative colitis with the use
of PN [2], [29]. There is no standardised data available
regardingtheremissionratewithPN.Itwasalsoobserved
that, in complicated cases, remission could be more
easily attained with PN than with enteral nutrition [15].
TotalPNisanimportanttherapyinchildrenandteenagers
[5].
In terms of wound healing and the reconstitution of the
small intestine, PN shows no advantages compared to
enteralnutrition.Itisassumedthatoral/enteralnutrition
provides faster stability in organ function of the small in-
testine.
Complications like venous thrombosis, occlusion of the
central venous vessels, sepsis, cholestasis/cholangit-
is/cholecystitis, cholestatic liver dysfunction are associ-
ated with TPN [16], [17], [19], [20], [21], [22], [24], [25],
[30].
Acute increase in transaminases, overall bilirubin and
albumin are characteristics of metabolic complications
of PN [16], [17], [19], [20], [21], [22], [24], [25], [30].
There are no advantages of PN therapy over enteral nu-
trition therapy regarding fistula healing. No differences
can be seen in the rate of survival.
Acute pancreatitis
Indication and time of PN
• Enteral nutrition is clearly superior to PN in severe,
acute pancreatitis (A).
• An intolerance to enteral nutrition results in an indica-
tionfortotalPNincomplicationssuchaspseudocysts,
intestinal and pancreatic fistulae, and pancreatic
abscesses or pancreatic ascites (B).
• Ifenteralnutritionisnotpossible,PNisrecommended,
at the earliest, 5 days after admission to the hospital
(C).
• TPN should be not be routinely administered in mild
acute pancreatitis or nil by moth status <7 days, due
to high costs and an increased risk of infection (C).
Commentary
The nutritional therapy of acute pancreatitis depends on
theseverityofthedisease,presenceofanycomplications
andnutritionalstateofthepatient.Enteraltransduodenal
feeding should be started once acute pancreatitis is
suspected. There is a clear benefit with enteral nutrition
innumerousstudies[31],[32],[33],[34],[35],[36],[37],
[38], [39], [40], [41] regarding LOS, infection-related
morbidity and possible organ failures. Total PN should
bestartedonlywhentherearecontraindicationstoenter-
al nutrition or no possible access.
The time to start should be after the resolution of the
acute phase in acute, complicated forms of pancreatitis
[42],[43].Aprospective,controlledandrandomisedstudy
on acute pancreatitis [44] shows that exclusive TPN re-
sults in a longer LOS and increase in costs with no im-
provement regarding the course of disease.
Recentstudieshaveshownthatenteralnutritionthrough
a jejunal tube can be of an advantage in specific patient
groups [45], [46], [47], [48]. A similarly positive effect is
alsoachievedbyusingnasogastrictubes,butinasmaller
study [49].
Jejunal feeding is assessed to be safe and effective in
the postoperative stage in severe forms of pancreatitis,
according to the study by Pupelis [45]. TPN is presumed
to prevent stimulation of the exocrine pancreas as well
as help in the maintenance of metabolic homeostasis in
severe forms of pancreatitis [17], [30]. In severe cases
(presence of ileus), the task of TPN is to compensate for
the increased protein expenditure, as well as to maintain
the nutrition state of the patient. PN reduces mortality
and improves the nutritional situation in such circum-
stances [50], [51], and is to be continued until a stable,
haemodynamic state is achieved [52], [53].
Thelackofutilisationoftheintestineinacutepancreatitis
seemstoworsenthemetabolicstresssituation,lengthen
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[40], [46], [54], [55]. Further evidence indicates that not
onlyenteralnutrition,butalsospecificnutritionalcompon-
ents in enteral nutrition such as probiotics, arginine,
glutamine and antioxidants have a positive influence on
LOS and the rate of complications [56], [57].
Energy intake
• The energy requirements lie in a range between 25
and 35 kcal/kg body weight/day [16] (A).
Substrate intake
• A standard solution including lipids can be admin-
istered in acute pancreatitis (C). Lipids can be admin-
istered to meet energy requirements and should be
subject to regular monitoring (triglycerides).
• Carbohydrates are the most important energy source.
Glucose administration (max. 4–5 g/kg body
weight/day) counteracts intrinsic gluconeogenesis,
and prevents protein degradation. Administering
glucoseinsteadoflipids,asanenergysupplier,lowers
the potential risk of hyperlipidemia, but lipid adminis-
tration cannot be avoided in most cases (B).
• An even nitrogen balance can be achieved and main-
tained with amino acids. The intake of amino acids
should be about 1.2–1.5 g/kg body weight/day (A).
• The additional enrichment of TPN with glutamine
should be considered in severe, progressive forms of
pancreatitis,therebyimprovingtheclinicalprogression
(B).
• The intravenous administration of lipid emulsions is
safe, as long as triglyceride levels (<400 mg/dl) are
monitored (C). Statements on particularly beneficial
fatty acid admixtures cannot be made regarding pan-
creatitis.
Commentary
McClave et al. [44] carried out a study in 1997, in which
30 patients received either total PN or total enteral nutri-
tion. No differences between the two groups were ob-
servedwithregardstomortality,levelofpainintheperiod
until amylase levels normalised, serum albumin levels
and the frequency of nosocomial infections. Significantly
morehyperglycaemiaoccurredinthetotalPNgroup[34].
Tests on fatty acid admixtures are at present only avail-
able for “Intralipid” solutions and are deemed safe for
administration [58].
The glucose admixture was modified in 2 studies [58],
[59]basedontheclinicalpictureofstress-inducedhyper-
glycaemia. In the study carried out by Wu [58], initial
hyperglycaemia was reported in 64% of patients, which
was easier to control with a lipid/glucose admixture than
in a pure glucose admixture. Hypertriglyceridemia, or
negative effects on the liver function, were not reported.
Significant differences regarding the glucose levels,
cholesterol levels or uric acid levels were also not re-
ported in Martinez' work [59].
De Beaux et al. [60] carried out a study of 14 patients
with acute pancreatitis, where one group received
standardised PN and the other group received nutrition
enriched with glutamine. The glutamine group showed
increased lymphocyte proliferation, an increase in T-cell
DNA as well as a drop in an interleukin 8 concentration.
The administration of glutamine could be beneficial in
preventing complications. A lower rate of complications
andsignificantlylowerratesofpancreaticinfectionswere
also described with glutamine in the papers by Ockenga
et al. [61] and Xian et al. [62]. Patients with acute pan-
creatitis show an increased rate of catheter-sepsis and
metabolic dysfunctions. The administration of thiamine,
folic acid, magnesium and zinc is recommended in pa-
tients with a history of alcohol abuse [17], [63].
Patients with severe diseases and complications require
early enteral nutritional therapy to prevent detrimental
effects caused by nutritional losses (especially proteins)
[32], [36], [64]. Some authors recommend early jejunal
nutrition with an elementary diet and others recommend
TPNcombinedwithenteralnutrition[65].PNshouldonly
be used in complicated cases when ileus is present or
probable with regular checks for glucose, triglycerides
and serum pH.
Notes
This article is part of the publication of the Guidelines on
Parenteral Nutrition from the German Society for Nutri-
tional Medicine (overview and corresponding address
under http://www.egms.de/en/gms/2009-7/000086.
shtml).
English version edited by Sabine Verwied-Jorky, Rashmi
Mittal and Berthold Koletzko, Univ. of Munich Medical
Centre, Munich, Germany.
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